November 30, 2022 Cerevance Announces Presentation of Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases – Biology and Therapeutics Conference and Publication in Neuropharmacology
November 15, 2022 Cerevance Announces Presentation of Preclinical Study Results at the Society for Neuroscience Conference
August 9, 2022 Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
June 8, 2022 Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention
April 19, 2022 Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
March 31, 2022 Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
